Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside

Background: Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 (HER2/neu) antibody, is considered a standard treatment in addition to chemotherapy in the adjuvant setting for HER2/neu-positive breast cancer, yet its impact on fertility and ovarian reserve remains obscure. We aime...

Descripción completa

Detalles Bibliográficos
Autores principales: Levi, Mattan, Goshen-Lago, Tal, Yerushalmi, Rinat, Granot, Tal, Stemmer, Salomon M., Shalgi, Ruth, Ben-Aharon, Irit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762209/
https://www.ncbi.nlm.nih.gov/pubmed/33297351
http://dx.doi.org/10.3390/biomedicines8120577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762209/
https://www.ncbi.nlm.nih.gov/pubmed/33297351
http://dx.doi.org/10.3390/biomedicines8120577

Ejemplares similares